Boehringer Ingelheim

Found 2254 clinical trials|View Analysis

Sort by:

Need a comprehensive medical report on "Boehringer Ingelheim"?

Analyze the latest clinical research and treatment options

Summarize scientific findings from medical journals

BI 695500 vs Rituxan First Line Treatment in Patients With Low Tumor Burden Follicular Lymphoma

Phase 3

Terminated

Conditions: Lymphoma, Non-Hodgkin

Interventions: Drug: BI 695500
Drug: Rituximab

First Posted Date: 2015-04-15

Last Posted Date: 2017-01-30

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 2

Registration Number: NCT02417129

Locations: 🇨🇿
Boehringer Ingelheim Investigational Site, Praha, Czech Republic

Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2)

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 1

Interventions: Drug: Empagliflozin
Drug: Placebo

First Posted Date: 2015-04-13

Last Posted Date: 2019-01-03

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 730

Registration Number: NCT02414958

Locations: 🇺🇸
Rocky Mountain Diabetes and Osteoporosis Center, Idaho Falls, Idaho, United States
🇺🇸
Northwest Endo Diabetes Research, LLC, Arlington Heights, Illinois, United States
🇺🇸
Office of Dr. Michelle Zaniewski-Singh, Houston, Texas, United States

and more 128 locations

Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers

Phase 1

Completed

Conditions: Schizophrenia
Alzheimer Disease

Interventions: Drug: Placebo matching BI 409306 25 mg
Drug: Placebo matching BI 409306 50 mg
Drug: BI 409306 25 mg
Drug: BI 409306 50 mg

First Posted Date: 2015-03-19

Last Posted Date: 2024-04-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 61

Registration Number: NCT02392468

Locations: 🇺🇸
Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States
🇺🇸
Community Clinical Research, Inc., Austin, Texas, United States
🇺🇸
University of California San Diego, La Jolla, California, United States

VARGADO - Vargatef in 2nd-line Therapy of Non-Small Cell Lung Cancer (NSCLC)

Active, not recruiting

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: treatment

First Posted Date: 2015-03-19

Last Posted Date: 2025-02-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 817

Registration Number: NCT02392455

Asthma Biomarker Study

Completed

Conditions: Asthma

Interventions: Procedure: Biofluid sampling

First Posted Date: 2015-03-19

Last Posted Date: 2018-08-29

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 69

Registration Number: NCT02392481

Locations: 🇬🇧
352.2087.44001 Boehringer Ingelheim Investigational Site, Leicester, United Kingdom
🇬🇧
352.2087.44004 Boehringer Ingelheim Investigational Site, London, United Kingdom
🇬🇧
352.2087.44002 Boehringer Ingelheim Investigational Site, Manchester, United Kingdom

and more 1 locations

Single Rising Dose Trial of BI 425809 for Healthy Japanese and Chinese Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: BI 425809

First Posted Date: 2015-03-10

Last Posted Date: 2015-08-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 49

Registration Number: NCT02383888

Locations: 🇰🇷
1346.4.82001 Boehringer Ingelheim Investigational Site, Busan, Korea, Republic of

Trial of Afatinib in Pediatric Tumours

Phase 1

Completed

Conditions: Neuroectodermal Tumors
Rhabdomyosarcoma

Interventions: Drug: afatinib

First Posted Date: 2015-02-26

Last Posted Date: 2021-03-04

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 56

Registration Number: NCT02372006

Locations: 🇫🇷
INS Curie, Paris, France
🇦🇺
Sydney Childrens Hospital, Randwick, New South Wales, Australia
🇫🇷
HOP Pellegrin, Bordeaux, France

and more 25 locations

Daily Use of JARDIANCE® Tablets in Japanese Elderly Patients With Type 2 Diabetes Mellitus

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: JARDIANCE®

First Posted Date: 2015-02-20

Last Posted Date: 2024-03-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 419

Registration Number: NCT02367131

Locations: 🇯🇵
NISND Center, Multiple Locations, Japan

Pharmacokinetics and Pharmacodynamic Effect of Different Multiple Oral Doses of BI 425809

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 425809

First Posted Date: 2015-02-13

Last Posted Date: 2015-07-02

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 25

Registration Number: NCT02362516

Locations: 🇧🇪
1346.3.32001 Boehringer Ingelheim Investigational Site, Antwerpen, Belgium

Uninterrupted Dabigatran Etexilate in Comparison to Uninterrupted Warfarin in Pulmonary Vein Ablation (RE-CIRCUIT)

Phase 4

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: Dabigatran Etexilate 150mg
Drug: Warfarin

First Posted Date: 2015-01-28

Last Posted Date: 2018-01-29

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 678

Registration Number: NCT02348723

Locations: 🇺🇸
Mercy Medical Group, a service of Dignity Health Medical Foundation, Sacramento, California, United States
🇺🇸
Southwest Florida Research, LLC, Naples, Florida, United States
🇺🇸
University of California, San Francisco, California, United States

and more 83 locations

AI-Powered Research

Premium Access

BI 695500 vs Rituxan First Line Treatment in Patients With Low Tumor Burden Follicular Lymphoma

Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2)

Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers

VARGADO - Vargatef in 2nd-line Therapy of Non-Small Cell Lung Cancer (NSCLC)

Asthma Biomarker Study

Single Rising Dose Trial of BI 425809 for Healthy Japanese and Chinese Male Subjects

Trial of Afatinib in Pediatric Tumours

Daily Use of JARDIANCE® Tablets in Japanese Elderly Patients With Type 2 Diabetes Mellitus

Pharmacokinetics and Pharmacodynamic Effect of Different Multiple Oral Doses of BI 425809

Uninterrupted Dabigatran Etexilate in Comparison to Uninterrupted Warfarin in Pulmonary Vein Ablation (RE-CIRCUIT)